NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Abstract 1010
Higher peripheral lymphocyte count to predict survival in triple-negative breast cancer (TNBC).

Poster Board: #115
Discussed at the Poster Discussion Session on Sunday, June 5, 2016, 4:45 PM - 6:00 PM, at Hall D2
Anosheh Afghahi, MD, MPH - Presenter
Stanford University School of Medicine

Abstract 1075
Prognostic utility of tumour infiltrating lymphocytes (TILs) and neutrophil-to-lymphocyte ratio (NLR) in early-stage triple negative breast cancer (TNBC).

Poster Board: #180
Antonia Pearson, BMed - Presenter
Medical Oncology Department, Royal North Shore Hospital

https://iplanner.asco.org/am2016/#/

Note: JMO, but the recent study from UCLA on the relationship between added survival with DCVax-L in GBM patients with higher TIL (but not with SOC patients alone), makes many cancers theoretically targetable by DCVax.